Cell-based high content screening using an integrated microfluidic device
Cell-based high content screening using an integrated microfluidic device
复制标题
使用集成微流体装置进行基于细胞的高内涵筛选
DOI：
10.1039/b711513j
复制
发表时间：
2007-01-01
期刊：
影响因子：
6.1
通讯作者：
Lin, Bingcheng
中科院分区：
文献类型：
--
作者：
Ye, Nannan;Qin, Jianhua;Lin, Bingcheng
高含量筛选（HCS）已迅速成为药物发现早期化合物二次筛选的核心技术。它允许在单次测定中测量单个细胞或细胞群中的几个独立的细胞参数。在这项工作中，我们描述了高内容筛选的多参数测量的细胞反应在人肝癌（HepG2）细胞使用集成的微流体装置。该装置由多个药物梯度发生器和平行的细胞培养室组成，其中液体稀释和扩散、微尺度细胞培养、细胞刺激和细胞标记的过程可以集成到单个装置中。简单的分析提供了多参数测量的质膜渗透性，核大小，线粒体跨膜电位和细胞内的氧化还原状态在抗癌药物诱导的HepG2细胞凋亡。所建立的平台能够以最少的样本和更少的时间从肿瘤细胞中快速提取响应于多种浓度变化的药物的最大信息，这对于基础生物医学研究和癌症治疗非常有用。
High content screening (HCS) has quickly established itself as a core technique in the early stage of drug discovery for secondary compound screening. It allows several independent cellular parameters to be measured in a single cell or populations of cells in a single assay. In this work, we describe high content screening for the multiparametric measurement of cellular responses in human liver carcinoma (HepG2) cells using an integrated microfluidic device. This device consists of multiple drug gradient generators and parallel cell culture chambers, in which the processes of liquid dilution and diffusion, micro-scale cell culture, cell stimulation and cell labeling can be integrated into a single device. The simple assay provides multiparametric measurements of plasma membrane permeability, nuclear size, mitochondrial transmembrane potential and intracellular redox states in anti-cancer drug-induced apoptosis of HepG2 cells. The established platform is able to rapidly extract the maximum of information from tumor cells in response to several drugs varying in concentration, with minimal sample and less time, which is very useful for basic biomedical research and cancer treatment.